Merck KGaA ADR MKKGY

Merck KGaA May Benefit From the Recent Life Science Reset Period Ending Soon

Merck KGaA has made a series of acquisitions and divestitures in the past decade or so to position the group for solid long-term growth in three key segments: life sciences, electronics, and healthcare. So although Merck is in the middle of a reset period following the pandemic boom years and although the biopharmaceutical pipeline has experienced a setback with evobrutinib (multiple sclerosis), we continue to have a positive view of the company's long-term prospects.